Filing Flows › Generate Biomedicines (GENB) › Q2 2026 › vs Q1 2026
Generate Biomedicines (GENB) Q2 2026 vs Q1 2026 (quarter over quarter)
Generate Biomedicines's revenue fell $910K (-13%) from $7.2M in Q1 2026 to $6.3M in Q2 2026.
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $6.3M | $7.2M | −$910K | -13% |
| Other income, net | $4.4M | $2.4M | $2.0M | +82% |
| Net loss | $67.3M | $61.7M | $5.5M | +9% |
| Costs & expenses | $78.0M | $71.4M | $6.6M | +9% |
| Operating costs | $77.9M | $71.3M | $6.6M | +9% |
| Income tax | $53K | $28K | $25K | +89% |
| Research & development | $64.3M | $57.8M | $6.5M | +11% |
| General & admin | $13.6M | $13.5M | $74K | +0.5% |
| Operating cash sources | $69.4M | $90.1M | −$20.7M | -23% |
| Depreciation & amortization | $3.2M | $3.3M | −$73K | -2% |
| Share-based compensation | $8.2M | $6.4M | $1.8M | +29% |
| Cash used in operations | $57.9M | $80.4M | −$22.4M | -28% |
| Net loss absorbed | $67.3M | $61.7M | $5.5M | +9% |
| Working capital & other | $2.1M | $28.3M | −$26.2M | -92% |
Questions
How much did Generate Biomedicines's revenue grow quarter over quarter in Q2 2026?
Generate Biomedicines's revenue fell $910K (-13%) from $7.2M in Q1 2026 to $6.3M in Q2 2026.